

## What's the value of your pharmacy?

Mike Jaczko, BSc. Phm, CIM®





#### **About Mike Jaczko**

- Pharmacist
- Partner and Portfolio with K J Harrison
- 32 years Merger & Acquisitions in Canadian retail pharmacy industry
- 19+ years experience in Canadian wealth management industry
- Trusted advisor to pharmacy owners
- Advisor on broader issues of wealth management







## Learning objectives

- Identify the most common methods used to valuate a Canadian retail pharmacy
- Understand the general difference between an asset and share deal
- Understand the importance of cash flow in two of the most respected valuation methods
- Understand the synergies between improving store cash flow and adding intrinsic value to your pharmacy business







#### Disclosure

 The presenter of this learning activity declares that he has no conflicts of interest to disclose with respect to the facilitation of this program.







# Profession of pharmacy and the business of pharmacy









## What are you valuing?

#### 







#### Asset sale

- Company is the "seller"
- Capital gains exemption is a non-issue
- Company assets are valued and sold
- Subsequently deposited into a new corporation
- Taxation occurs in:
  - the seller corporation
  - paid personally by seller to get proceeds out







## Selling shares

- Shareholder is selling the shares of the corporation
- Buyer purchasing shares
- Ownership is passed
- Corporation lives on
- Purchaser inherits liabilities as well







#### Asset versus share deal?

## Asset

- Preferred by buyer
- Higher due to tax shield implications

# Share


- Preferred by sellers
- QSBC exemption \$800K
- Majority of transactions







## The relationship









#### Cash flow

- EBITDA
- Earnings before interest, taxes, depreciation and amortization
- Normalization important process
- Key element in two major valuation models







## Valuation considerations

- Various methods:
  - \$/script, sales multiple extremely crude
  - Retrospective Cash flow multiple
  - Prospective Discounted cash flow
- Asset vs. share deal
- Intrinsic Value versus Market Value versus Sale Value
- Driving Market Value (price discovery) drives the Sale Value
  - An art (price discovery)
  - Establishing internal valuation based on cash flow
  - Validated by the ability to service debt







#### Retrospective valuation

- Multiple of normalized earnings
- Most widely used

Three components added to get final price:

- EBITDA X Multiple = Goodwill +
- Net Tangible Book Value Adjustment =\$+ inv + A/R A/P + Accruals +
- 3. Redundant Assets (e.g. building, land marketable securities)
  - = Total price







#### Prospective valuation

- Forwarding looking develop
  - "Proforma" five to 10 years
  - Measure the cash flow each year
- DCF Discount back to a "present value"
- Forms the basis for the "Goodwill"
- Used by sophisticated buyers
- Useful to measure debt servicing







## Example debt servicing schedule


Total 2012 Cash Price Interest Rate Term (months) Amortization (months)	\$4,320,000 6% 60 120									
	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Estimatd Maintable EBIT-DA (as projected) Deduct Interest Charges (current)	\$870,519	\$904,112	\$938,862	\$974,808	\$1,011,987	\$1,062,586	\$1,094,464	\$1,127,298	\$1,161,117	\$1,195,950
Deduct Interest Charges (proposed)	\$250,354	\$230,298	\$209,204	\$186,398	\$162,397	\$136,916	\$109,864	\$81,143	\$50,650	\$18,276
Pre-Tax Debt Adjusted Earnings Less Income Tax Small Business Rate @ 15.5%	\$620,165	\$673,814	\$729,658	\$788,410	\$849,590	\$925,670	\$984,600	\$1,046,155	\$1,110,467	\$1,177,674
For First \$500,000	-\$77,500	-\$77,500	-\$77,500	-\$77,500	-\$77,500	-\$77,500	-\$77,500	-\$77,500	-\$77,500	-\$77,500
Prescribed Rate thereafter	-\$32,445	-\$46,930	-\$62,008	-\$77,871	-\$94,389	-\$114,931	-\$130,842	-\$147,462	-\$164,826	-\$182,972
Total Taxes	-\$109,945	-\$124,430	-\$139,508	-\$155,371	-\$171,889	-\$192,431	-\$208,342	-\$224,962	-\$242,326	-\$260,472
Net After Tax earnings	\$510,220	\$549,384	\$590,150	\$633,039	\$677,701	\$733,239	\$776,258	\$821,193	\$868,141	\$917,202
Deduct Net Sustaining CapEx	-\$12,176	-\$12,419	-\$12,667	-\$12,921	-\$13,179	-\$13,443	-\$13,846	-\$14,262	-\$14,690	-\$15,131
Adjusted Discretionary Cash Flow	\$498,044	\$536,965	\$577,483	\$620,118	\$664,522	\$719,796	\$762,412	\$806,931	\$853,451	\$902,072
Deduct Principal Due	\$325,176	\$345,232	\$366,326	\$389,132	\$413,133	\$438,614	\$465,666	\$494,387	\$524,880	\$557,254
Net Cash Flow	\$172,868	\$191,733	\$211,157	\$230,986	\$251,389	\$281,182	\$296,746	\$312,544	\$328,571	\$344,818
Cumulative Cash Flow	\$172,868	\$364,602	\$575,759	\$806,745	\$1,058,134	\$1,339,316	\$1,636,062	\$1,948,606	\$2,277,177	\$2,621,995







## The relationship









#### Program learning objectives

- Identify the most common methods used to valuate a Canadian retail pharmacy
- Understand the general difference between an asset and share deal
- Understand the importance of cash flow in two of the most respected valuation methods
- 4. Understand the synergies between improving store cash flow and adding intrinsic value to your pharmacy business







#### More information

- http://www.kjharrison.com/advice/mjaczko
- Articles 4 & 5









#### **Questions?**

#### **Contact Information:**

Mike Jaczko, Pharmacist, Partner & Portfolio Manager

Direct Line: 416.867.8251

Email: mjaczko@kjharrison.com

Website: http://www.kjharrison.com/

Webcast: <a href="http://www.kjharrison.com/private-client-business">http://www.kjharrison.com/private-client-business</a>



